



STAFF REPORT

# Pharmaceuticals for Women's Health:

*Global Markets to 2023*

August 2018

***BCC Research Staff***

Report Code: PHM203A



# Table of Contents

<b>Chapter 1: Introduction</b> .....	<b>1</b>
Study Goals and Objectives.....	1
Reasons for Doing This Study.....	1
Scope of Report.....	2
Information Sources.....	2
Methodology.....	3
Geographic Breakdown.....	3
Analyst's Credentials.....	7
Related BCC Research Reports.....	7
<b>Chapter 2: Summary and Highlights</b> .....	<b>9</b>
<b>Chapter 3: Technologies and Global Markets Overview</b> .....	<b>13</b>
Disease Overview and Definitions .....	13
Market Driving Factors and Opportunities .....	14
Aging Female Population.....	14
Government Involvement and Increased Funding.....	18
Increasing Awareness Regarding Women's Disorders and Treatments .....	20
Market Restraints .....	21
Poor Diagnosis.....	21
Availability of Alternate Treatment Options and Lifestyle Changes .....	22
Unavailability of Novel Treatments.....	22
High Cost of Treatment .....	23
<b>Chapter 4: Pipeline Assessment and Analysis</b> .....	<b>25</b>
List of Drugs in Pipeline.....	25
Overview of Osteoporosis Drug Development Pipeline.....	28
Late-stage Pipeline Drugs.....	29
Elagolix (AbbVie Inc.) .....	29
Vilaprisan (Bayer AG).....	30
Evenity (Amgen Inc.).....	30
Relugolix (Myovant Sciences) .....	31
Proellex (Repros Therapeutics).....	31
Esmya (Allergan Inc.) .....	32
TX-004HR (TherapeuticsMD, Inc.) .....	33
TX-001HR (TherapeuticsMD, Inc.) .....	34
<b>Chapter 5: Regulatory Structure</b> .....	<b>36</b>
Overview of Regulations .....	36
United States.....	36
Canada .....	37
Europe.....	37
Japan .....	38
Overview of Pricing and Reimbursement .....	38
United States.....	38
Canada .....	41
Europe.....	41
Japan.....	42

<b>Chapter 6: Market Breakdown by Women’s Health Disorders.....</b>	<b>44</b>
Introduction .....	44
Menopause-Related Diseases.....	47
Overview.....	47
Symptoms.....	48
Risk Factors.....	49
Epidemiology and Economic Burden.....	49
Diagnosis.....	50
Treatments .....	50
Market Size and Forecasts .....	54
Postmenopausal Osteoporosis .....	56
Overview.....	56
Epidemiology and Economic Burden.....	57
Diagnosis.....	57
Treatments .....	58
Market Size and Forecasts .....	63
Endometriosis .....	67
Overview.....	67
Epidemiology and Economic Burden.....	68
Diagnosis.....	68
Treatments .....	69
Market Size and Forecasts .....	71
Polycystic Ovary Syndrome (PCOS).....	73
Overview.....	73
Reducing the Risk of PCOS .....	74
Epidemiology and Economic Burden.....	74
Diagnosis.....	75
Treatments .....	75
Market Size and Forecasts .....	76
Pregnancy Disorders and Management.....	78
Overview.....	78
Market Size and Forecasts .....	79
Others .....	81
Overview.....	81
Market Size and Forecasts .....	81
<b>Chapter 7: Market Breakdown by Region .....</b>	<b>85</b>
Introduction .....	85
North America.....	87
United States.....	91
Canada .....	93
Mexico .....	94
Europe.....	95
United Kingdom .....	100
Germany .....	101
France .....	102
Spain.....	103
Italy .....	104
Rest of Europe.....	105
Asia-Pacific .....	106
China .....	111

Japan .....	112
India .....	113
South Korea .....	114
Rest of Asia-Pacific.....	115
South America.....	116
Middle East and Africa .....	120
<b>Chapter 8: Competitive Landscape and Key Developments .....</b>	<b>125</b>
Market Players and Strategy.....	125
Patent Analysis.....	128
List of Key Patents .....	128
Key Developments .....	129
Mergers and Acquisitions.....	129
Development of Innovative Products/Novel Product Launch.....	130
Agreements, Collaborations & Partnerships .....	130
Key Products .....	132
<b>Chapter 9: Company Profiles .....</b>	<b>135</b>
<b>Appendix.....</b>	<b>167</b>
Abbreviations Used in the Report.....	169
<b>About BCC Research.....</b>	<b>172</b>
About BCC Research.....	173
BCC Membership .....	173
BCC Custom Research .....	173

# List of Tables

Summary Table Global Market for Women’s Health Therapeutics, by Disease Area, Through 2023 (\$ Millions) .....	10
Table 1 Life Expectancy at Birth, Both Sexes Combined, by Region (Years) .....	15
Table 2 Pipeline Molecules, Endometriosis .....	25
Table 3 Pipeline Molecules, Uterine Fibroids .....	26
Table 4 Pipeline Molecules, All Other Indications .....	27
Table 5 Pipeline Molecules, Osteoporosis .....	28
Table 6 Elagolix Snapshot.....	29
Table 7 Vilaprisan Snapshot.....	30
Table 8 Evenity Snapshot .....	31
Table 9 Relugolix Snapshot .....	31
Table 10 Proellex Snapshot.....	32
Table 11 Esmya Snapshot .....	33
Table 12 TX-004HR Snapshot.....	33
Table 13 TX-001HR Snapshot.....	34
Table 14 Global Market for Women’s Health Therapeutics, by Disease Area, Through 2023 (\$ Millions) .....	44
Table 15 FDA Approved Estrogen-only Medicines.....	50
Table 16 FDA Approved Progestin-only Medicines.....	51
Table 17 FDA Approved Combination, Estrogen and Progestin Medicines.....	51
Table 18 FDA Approved Combination Estrogen and Hormone Medicines.....	51
Table 19 Vagifem (10mcg), Patent Expiration .....	52
Table 20 Global Menopause Market, by Region, Through 2023 (\$ Millions) .....	55
Table 21 Prolia/XGEVA (Denosumab) Patent Expiration .....	59
Table 22 Global Postmenopausal Osteoporosis Market, by Region, Through 2023 (\$ Millions) .....	66
Table 23 Global Endometriosis Market, by Region, Through 2023 (\$ Millions) .....	72
Table 24 Global Polycystic Ovary Syndrome Market, by Region, Through 2023 (\$ Millions).....	77
Table 25 Global Pregnancy Disorders and Management Market, by Region, Through 2023 (\$ Millions) ..	80
Table 26 Global Women’s Health Therapeutics Others Market, by Region, Through 2023 (\$ Millions) ...	82
Table 27 Global Women’s Health Therapeutics, by Region, Through 2023 (\$ Millions) .....	85
Table 28 North American Market for Women’s Health Therapeutics, by Disease Area Through 2023 (\$ Millions) .....	87
Table 29 European Market for Women’s Health Therapeutics, by Disease Area, Through 2023 (\$ Millions) .....	95
Table 30 Asia Pacific Market for Women’s Health Therapeutics, by Disease Area, Through 2023 (\$ Millions) .....	106
Table 31 South America Market for Women’s Health Therapeutics, by Disease Area, Through 2023 (\$ Millions) .....	116
Table 32 Middle East and Africa Market for Women’s Health Therapeutics, by Disease Area, Through 2023 (\$ Millions) .....	120
Table 33 Company Share Analysis, by Indication, 2017 (%) .....	125
Table 34 Tier III Companies.....	127
Table 35 Patent Review .....	128
Table 36 Marketed Products, Postmenopausal Osteoporosis.....	132
Table 37 AbbVie Inc., Marketed Products .....	135
Table 38 AbbVie Inc., Net Revenue, 2015-2017 (\$ Millions) .....	136
Table 39 Allergan Plc., Marketed Products.....	138
Table 40 Allergan Plc., Net Revenue, 2015-2017 (\$ Millions).....	139

Table 41 Amgen Inc., Marketed Products, 2016.....	140
Table 42 Amgen Inc.: Net Revenue, 2015–2017 (\$ Millions).....	142
Table 43 Bayer AG, Marketed Products.....	143
Table 44 Bayer AG, Net Revenue, 2015-2017 (\$ Millions).....	144
Table 45 Daiichi Sankyo Company. Ltd., Marketed Products.....	147
Table 46 Daiichi Sankyo Company Ltd. Net Revenue 2015-2017 (\$ Millions).....	148
Table 47 Eli Lilly and Company, Marketed Products.....	149
Table 48 Eli Lilly and Company Net Revenue, 2015-2017 (\$ Millions).....	150
Table 49 Johnson & Johnson Inc., Marketed Products, 2016.....	152
Table 50 Johnson & Johnson Inc. Net Revenue, 2014-2016 (\$ Millions).....	153
Table 51 Merck & Co. Inc., Marketed Products.....	155
Table 52 Merck & Co. Inc. Net Revenue, 2014–2016 (\$ Millions).....	156
Table 53 Merck KGaA Marketed Products.....	158
Table 54 Novo Nordisk, Marketed Products.....	159
Table 55 Novo Nordisk, Net Revenue, 2015–2017 (\$ Millions).....	159
Table 56 Pfizer Inc. Marketed Products by Indication, 2016.....	162
Table 57 Pfizer Inc. Net Revenue, 2014–2016 (\$ Millions).....	163
Table 58 Glossary of Terms Used in Women’s Health Therapeutics.....	167
Table 59 Abbreviations Used in Women’s Health Therapeutics.....	169

# List of Figures

Summary Figure Global Market for Women’s Health Therapeutics, by Disease Area, 2017-2023 (\$ Millions) .....	11
Figure 1 Older Population Distribution, by Age Group and Sex, 2017 (%) .....	16
Figure 2 Older Population Distribution, by Age Group and Sex, 2050 (%) .....	17
Figure 3 Funding for Research, Disease Condition/Category, 2014-2016 (\$ Millions) .....	18
Figure 4 Funding for Research, Women’s Health, 2014-2016 (\$ Millions) .....	19
Figure 5 Insurance Coverage in the U.S., by Healthcare Providers, 2014 (%) .....	20
Figure 6 Global Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	45
Figure 7 Global Women’s Health Therapeutics Market Share, by Disease Area, 2018 (%) .....	46
Figure 8 Global Women’s Health Therapeutics Market Share, by Disease Area, 2023 (%) .....	47
Figure 9 Global Menopause Market, 2017-2023 (\$ Millions) .....	54
Figure 10 Global Menopause Market, by Region, 2017-2023 (\$ Millions) .....	55
Figure 11 Australia Rate of Hospitalization for Osteoporosis, People Aged 50 and Over, 2015-2016 (Per 100,000 Population) .....	64
Figure 12 Global Postmenopausal Osteoporosis Market, 2017-2023 (\$ Millions) .....	65
Figure 13 Global Postmenopausal Osteoporosis Market, by Region, 2017-2023 (\$ Millions) .....	67
Figure 14 Global Endometriosis Market, 2017-2023 (\$ Millions) .....	72
Figure 15 Global Endometriosis Market, by Region, 2017-2023 (\$ Millions) .....	73
Figure 16 Global Polycystic Ovary Syndrome Market, 2017-2023 (\$ Millions) .....	77
Figure 17 Global Polycystic Ovary Syndrome Market, by Region, 2017-2023 (\$ Millions) .....	78
Figure 18 Global Pregnancy Disorders and Management Market, 2017-2023 (\$ Millions) .....	79
Figure 19 Global Pregnancy Disorders and Management Market, by Region, 2017-2023 (\$ Millions) .....	80
Figure 20 Global Women’s Health Therapeutics Market for Others, 2017-2023 (\$ Millions) .....	82
Figure 21 Global Women’s Health Therapeutics Others Market, 2017-2023 (\$ Millions) .....	83
Figure 22 Global Women’s Health Therapeutics Market, by Region, 2017-2023 (\$ Millions) .....	86
Figure 23 North America Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	88
Figure 24 North America Women’s Health Therapeutics Market Share, by Disease Area, 2018 (%) .....	89
Figure 25 North America Women’s Health Therapeutics Market Share, by Disease Area, 2023 (%) .....	90
Figure 26 North America Market for Women’s Health Therapeutics, by Country, 2017-2023 (\$ Millions) .....	91
Figure 27 United States Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	92
Figure 28 Canada Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	93
Figure 29 Mexico Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	94
Figure 30 Europe Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	96
Figure 31 Europe Women’s Health Therapeutics Market Share, by Disease Area, 2018 (%) .....	97
Figure 32 Europe Women’s Health Therapeutics Market Share, by Disease Area, 2023 (%) .....	98
Figure 33 Europe Market for Women’s Health Therapeutics, by Country, 2017-2023 (\$ Millions) .....	99
Figure 34 United Kingdom Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	100
Figure 35 Germany Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	101
Figure 36 France Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	102
Figure 37 Spain Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	103
Figure 38 Italy Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	104
Figure 39 Rest of Europe Women’s Health Therapeutics Market, 2017- 2023 (\$ Millions) .....	105
Figure 40 Asia-Pacific Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	107
Figure 41 Asia-Pacific Women’s Health Therapeutics Market Share, by Disease Area, 2018 (%) .....	108
Figure 42 Asia-Pacific Women’s Health Therapeutics Market Share, by Disease Area, 2023 (%) .....	109
Figure 43 Asia Pacific Market for Women’s Health Therapeutics, by Country, 2017-2023 (\$ Millions) ..	110

Figure 44 China Women’s Health Therapeutics Market, 2017-2023 (\$ Millions).....	111
Figure 45 Japan Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	112
Figure 46 India Women’s Health Therapeutics Market, 2017-2023 (\$ Millions).....	113
Figure 47 South Korea Women’s Health Therapeutics Market, 2017-2023 (\$ Millions).....	114
Figure 48 Asia-Pacific Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	115
Figure 49 South America Women’s Health Therapeutics Market, 2017-2023 (\$ Millions) .....	117
Figure 50 South America Women’s Health Therapeutics Market Share, by Disease Area, 2018 (%).....	118
Figure 51 South America Women’s Health Therapeutics Market Share, by Disease Area, 2023.....	119
(%) .....	119
Figure 52 Middle East & Africa Women’s Health Therapeutics Market, 2017-2023 (\$ Millions).....	121
Figure 53 Middle East & Africa Women’s Health Therapeutics Market Share, by Disease Area, 2018 (%) .....	122
.....	123
Figure 54 Middle East & Africa Women’s Health Therapeutics Market Share, by Disease Area, 2023 (%) .....	123
.....	126
Figure 55 Global Women’s Health Therapeutics Market Share Analysis, 2017 (%) .....	126
Figure 56 AbbVie Inc., Revenue Share, by Region, 2016 (%) .....	137
Figure 57 Allergan PLC., Revenue Share, by Business Segment, 2016 (%) .....	139
Figure 58 Amgen Inc. R&D Expenditure, 2014-2016 (\$ Billions) .....	141
Figure 59 Amgen Inc.: Revenue Share, by Region, 2017 (%) .....	142
Figure 60 Bayer AG, Revenue Share, by Region, 2017 (%) .....	145
Figure 61 Bayer AG, Revenue Share, by Business Segment, 2017 (%) .....	146
Figure 62 Daiichi Sankyo Company. Ltd., R&D Expenditure, 2014–2016 (\$ Billions) .....	147
Figure 63 Daiichi Sankyo Company Revenue Share by Business Segment, 2016 (%) .....	148
Figure 64 Eli Lilly and Company Revenue Share by Business Segment, 2016 (%) .....	150
Figure 65 Eli Lilly and Company Revenue Share by Region, 2016 (%) .....	151
Figure 66 Johnson and Johnson Inc. Revenue Share, by Business Segment, 2016 (%) .....	153
Figure 67 Johnson and Johnson Inc. Revenue Share, by Region, 2016 (%) .....	154
Figure 68 Merck & Co. Inc. Revenue Share by Business Segment, 2016 (%).....	156
Figure 69 Merck & Co. Inc. Revenue Share by Region, 2016.....	157
Figure 70 Novo Nordisk, Revenue Share, by Region, 2016 (%) .....	160
Figure 71 Novo Nordisk, Revenue Share, by Business Segment, 2016 (%) .....	161
Figure 72 Pfizer Inc. Revenue Share, by Region, 2016 (%).....	164
Figure 73 Pfizer Inc. Revenue Share, by Business Segment, 2016 (%).....	165





*About BCC Research*

## *About BCC Research*

With our unparalleled 45-year history, BCC Research provides comprehensive analysis of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

## *BCC Membership*

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price towards a full membership. Call 866/285-7215 or email [info@bccresearch.com](mailto:info@bccresearch.com) to request a demo.

## *BCC Custom Research*

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: [custom@bccresearch.com](mailto:custom@bccresearch.com) or 781-205-2429.

## DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 978-1-62296-795-7  
August 2018